PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07739537

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose other
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07739537
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07739537. Allocation not applicable; no masking; primary purpose other. Start 2026-10-01 (anticipated); primary completion 2029-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic Responses
Acronym
PATHS-T2D
Condition
Diabete Type 2
Condition
Pharmacogenomic Drug Interaction
Intervention (Drug)
Orforglipron
Lead sponsor
Massachusetts General Hospital (class: other)

Record details

Record id
cardio:ct-nct07739537
Content hash
24a5ee46ab6e76de1bc9b131dd58b349ae62b0608e3aaca20a16a9f5caf3f268